User Notice: The site will be occasionally unavailable due to scheduled maintenance this weekend. Please accept our apologies for any inconvenience.


Ionis Pharmaceuticals Stock Price

-0.57 (-1.53%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Ionis Pharmaceuticals Inc IONS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.57 -1.53% 36.76 15:31:47
Open Price Low Price High Price Close Price Prev Close
37.53 36.37 39.34 37.33
Bid Price Ask Price Spread News
36.78 36.80 0.02 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
21,458 2,078,787 $ 37.49 $ 77,928,447 1,655,190 36.03 - 64.37
Last Trade Time Type Quantity Stock Price Currency
15:31:47 100 $ 36.76 USD

Ionis Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 5.19B 140.93M 118.88M $ 729.26M $ -524.12M -3.23 -13.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% -25.74k 0.50%

more financials information »

Ionis Pharmaceuticals News

Date Time Source News Article
5/06/202107:05PR Newswire (US)Ionis to present at upcoming investor conferences
5/05/202116:05PR Newswire (US)Ionis to host 2021 virtual annual meeting of stockholders
5/05/202114:59Edgar (US Regulatory)Quarterly Report (10-q)
5/05/202111:16Edgar (US Regulatory)Current Report Filing (8-k)
5/05/202108:06Seeking AlphaIonis Pharma trails Q1 consensus; top-line off 16%
5/05/202107:02Seeking AlphaIonis Pharmaceuticals EPS misses by $0.09, misses on revenue
5/05/202107:00PR Newswire (US)Ionis reports first quarter 2021 financial results and..
5/04/202114:05Seeking AlphaIonis Pharmaceuticals Q1 2021 Earnings Preview
4/21/202107:05PR Newswire (US)Ionis to hold first quarter 2021 financial results webcast
4/20/202107:32Seeking AlphaIonis begins pivotal study for ION373 in rare congenital..
4/20/202107:05PR Newswire (US)Ionis initiates pivotal clinical study of novel antisense..
4/19/202117:05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IONS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week43.3243.9036.0340.252,167,828-6.56-15.14%
1 Month42.5044.1036.0341.271,562,761-5.74-13.51%
3 Months58.0060.1536.0345.771,469,802-21.24-36.62%
6 Months49.8764.3736.0350.101,256,032-13.11-26.29%
1 Year56.6864.3736.0351.381,056,029-19.92-35.14%
3 Years44.1488.707536.0355.791,056,030-7.38-16.72%
5 Years34.0188.707519.592748.491,296,4172.758.09%

Ionis Pharmaceuticals Description

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Your Recent History
Ionis Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210507 19:46:50